FT Pharma 2013: AstraZeneca CEO Pascal Soriot on Brilinta, MedImmune and the UK's 'Golden Triangle'

The UK’s ‘Golden Triangle’ of biotech innovation can compete on the world stage, AstraZeneca (LSE: AZN) chief executive Pascal Soriot told the Financial Times Global Pharmaceutical & Biotechnology Conference in London today.

Mr Soriot gave the opening Keynote Interview at the conference attended by key industry figures from around the world. He said the Anglo-Swedish company is “committed to the UK”, speaking of its relocation to Cambridge Biomedical Campus in 2016. It announced last month that some teams will make the move as early as next year.

He said: “In Cambridge we will be part of the science research hub, surrounded by the most prestigious institutions in the world. The Golden Triangle of Cambridge, Oxford and London can compete on a global scale. We’re very committed to being in the Golden Triangle; it’s one of the most prestigious centres in the world.”